Redirecting T cells

New England Journal of Medicine

Volumn 365, Issue 8, 2011, Pages 754-757

  Urba, Walter J ^a   Longo, Dan L ^b  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 6; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; PENTOSTATIN; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER REGRESSION; CELL DIVISION; CELL PROLIFERATION; CELL SPECIFICITY; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; EDITORIAL; EPSTEIN BARR VIRUS; GENE TRANSFER; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MELANOMA; MEMORY CELL; PATIENT SAFETY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR LYSIS SYNDROME; CHIMERA; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHATIC LEUKEMIA; LYMPHOCYTE ACTIVATION; NOTE; REMISSION;

ANTIGENS, CD19; ANTIGENS, CD28; CHIMERA; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOID; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; T-LYMPHOCYTES;

EID: 80052139996     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1106965     Document Type: Editorial

References (10)

1. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529-33.
2. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virusinduced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-55. (Pubitemid 28406858)
3. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7.
4. Cartellieri M, Bachmann M, Feldmann A, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotech 2010;2010:956304 (Epub 2010 May 5).
5. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
6. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
7. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010;18:666-8.
8. Heslop HE. Safer CARS. Mol Ther 2010;18:661-2.
9. Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19- specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010;24:1160-70.
10. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.